SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-22-020866
Filing Date
2022-08-04
Accepted
2022-08-04 07:40:17
Documents
72
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q avtx-20220630.htm   iXBRL 10-Q 1437624
2 EX-31.1 ex311avtx2q2022.htm EX-31.1 11661
3 EX-31.2 ex-312avtx2q2022.htm EX-31.2 11550
4 EX-32.1 ex-321avtx2q2022.htm EX-32.1 10105
10 GRAPHIC avtx-20220630_g1.jpg GRAPHIC 516333
  Complete submission text file 0001628280-22-020866.txt   8623277

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT avtx-20220630.xsd EX-101.SCH 57097
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT avtx-20220630_cal.xml EX-101.CAL 62845
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT avtx-20220630_def.xml EX-101.DEF 351171
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT avtx-20220630_lab.xml EX-101.LAB 691838
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT avtx-20220630_pre.xml EX-101.PRE 466908
66 EXTRACTED XBRL INSTANCE DOCUMENT avtx-20220630_htm.xml XML 1320033
Mailing Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850
Business Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850 410-522-8707
Avalo Therapeutics, Inc. (Filer) CIK: 0001534120 (see all company filings)

IRS No.: 450705648 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37590 | Film No.: 221134733
SIC: 2834 Pharmaceutical Preparations